Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Rachel Hopps"'
Autor:
Jeffrey S Miller, Behiye Kodal, Martin Felices, Peter Hinderlie, Michael F Kaminski, Laura Bendzick, Rachel Hopps, Marissa Kauffman, Yvette Soignier, Joshua T Walker, Todd R Lenvik, Melissa A Geller
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 9 (2022)
Background The tumor microenvironment contains stromal cells, including endothelial cells and fibroblasts, that aid tumor growth and impair immune cell function. Many solid tumors remain difficult to cure because of tumor-promoting stromal cells, but
Externí odkaz:
https://doaj.org/article/493a148c4e544ff7b54acc09de5b0af3
Autor:
Jacob A. Myers, Dawn Schirm, Laura Bendzick, Rachel Hopps, Carly Selleck, Peter Hinderlie, Martin Felices, Jeffrey S. Miller
Publikováno v:
JCI Insight, Vol 7, Iss 15 (2022)
NK cell exhaustion is caused by chronic exposure to activating stimuli during viral infection, tumorigenesis, and prolonged cytokine treatment. Evidence suggests that exhaustion may play a role in disease progression. However, relative to T cell exha
Externí odkaz:
https://doaj.org/article/e211990c9b894408b4da9c8f4a284746
Autor:
Jianbo Yang, Qianjin Liao, Matthew Price, Branden Moriarity, Natalie Wolf, Martin Felices, Jeffrey S. Miller, Melissa A. Geller, Laura Bendzick, Rachel Hopps, Timothy K. Starr, Christine H. O'Connor, Sarah Tarullo, Andrew C. Nelson, Eva Turley, Jing Wang, James B. McCarthy
Publikováno v:
Translational Oncology, Vol 16, Iss , Pp 101318- (2022)
Epithelial ovarian cancer (EOC) is a highly heterogeneous disease encompassing several distinct molecular subtypes and clinical entities. Despite the initial success of surgical debulking and adjuvant chemotherapy, recurrence with chemotherapy resist
Externí odkaz:
https://doaj.org/article/652d0641e7444755a9bac2d67231898f
Autor:
Martin Felices, Erin Wesley, Laura E. Bendzick, Behiye Kodal, Rachel Hopps, Bartosz Grzywacz, Peter Hinderlie, Jeffrey S. Miller, Melissa A. Geller
Publikováno v:
Cancer Immunology Research. 11:674-686
Immune checkpoint blockade (ICB) has changed the standard of care for many patients with cancer, yet no ICB is approved for ovarian cancer. We hypothesized that maintenance therapy with an IL15 “superagonist” (N-803) and ICB in combination could
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b1bc17b2cc5573193da7ce170083ac5d
https://doi.org/10.1158/2326-6066.cir-22-0600
https://doi.org/10.1158/2326-6066.cir-22-0600
Autor:
Melissa A. Geller, Jeffrey S. Miller, Peter Hinderlie, Bartosz Grzywacz, Rachel Hopps, Behiye Kodal, Laura E. Bendzick, Erin Wesley, Martin Felices
Supplemental Table 1 and Supplemental Figures 1-5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09cfde176cd63360fc9197e46f246c01
https://doi.org/10.1158/2326-6066.22736985
https://doi.org/10.1158/2326-6066.22736985
Autor:
Melissa A. Geller, Jeffrey S. Miller, Peter Hinderlie, Bartosz Grzywacz, Rachel Hopps, Behiye Kodal, Laura E. Bendzick, Erin Wesley, Martin Felices
Immune checkpoint blockade (ICB) has changed the standard of care for many patients with cancer, yet no ICB is approved for ovarian cancer. We hypothesized that maintenance therapy with an IL15 “superagonist” (N-803) and ICB in combination could
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69a446915008eb4d232dac5ba21dbf12
https://doi.org/10.1158/2326-6066.c.6551230.v1
https://doi.org/10.1158/2326-6066.c.6551230.v1
Autor:
Michael F Kaminski, Laura Bendzick, Rachel Hopps, Marissa Kauffman, Behiye Kodal, Yvette Soignier, Peter Hinderlie, Joshua T Walker, Todd R Lenvik, Melissa A Geller, Jeffrey S Miller, Martin Felices
Publikováno v:
Journal for ImmunoTherapy of Cancer. 10:e004725
BackgroundThe tumor microenvironment contains stromal cells, including endothelial cells and fibroblasts, that aid tumor growth and impair immune cell function. Many solid tumors remain difficult to cure because of tumor-promoting stromal cells, but
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5a35e861381aece9fd9b3c3875d6cd0
https://doi.org/10.1136/jitc-2022-004725
https://doi.org/10.1136/jitc-2022-004725
Autor:
Martin Felices, Michael Kaminski, Peter Hinderlie, Rachel Hopps, Laura Bendzick, Melissa Geller, Jeffrey S. Miller
Publikováno v:
Cancer Research. 82:2878-2878
Immunotherapies for solid tumors need to overcome barriers within the solid tumor microenvironment (TME), including stromal cells, cancer-associated fibroblasts, endothelial cells, pericytes, and immune cells. These can comprise a significant portion
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::43c2a4a1388258170957b96cad730bb5
https://doi.org/10.1158/1538-7445.am2022-2878
https://doi.org/10.1158/1538-7445.am2022-2878